High c-Met expression in stage I-II pancreatic adenocarcinoma: Proposal for an immunostaining scoring method and correlation with poor prognosis

Histopathology

Volumn 67, Issue 5, 2015, Pages 664-676

  Neuzillet, Cindy ^a,b,c   Couvelard, Anne ^a,b,c   Tijeras Raballand, Annemilaï ^d   de Mestier, Louis ^a   de Gramont, Armand ^e   Bédossa, Pierre ^a,b,c   Paradis, Valérie ^a,b,c   Sauvanet, Alain ^b,c   Bachet, Jean Baptiste ^f   Ruszniewski, Philippe ^a,b,c   Raymond, Eric ^e   Hammel, Pascal ^a,b,c   Cros, Jérôme ^a,b,c  

^a INSERM   (France)

^b BEAUJON HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d AAREC Filia Research   (France)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Biomarker; Immunochemistry; Invasion; Pancreatic cancer; Survival

Indexed keywords

SCATTER FACTOR RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR CELL; BIOSYNTHESIS; CANCER STAGING; KAPLAN MEIER METHOD; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MET; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS;

EID: 84943359065     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12691     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60; 277-300.
2. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010; 127; 2893-2917.
3. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 2010; 362; 1605-1617.
4. Rhim AD, Mirek ET, Aiello NM et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012; 148; 349-361.
5. Erkan M, Hausmann S, Michalski CW et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat. Rev. Gastroenterol. Hepatol. 2012; 9; 454-467.
6. Neesse A, Michl P, Frese KK et al. Stromal biology and therapy in pancreatic cancer. Gut 2011; 60; 861-868.
7. Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br. J. Cancer 2013; 108; 1-8.
8. Erkan M. The role of pancreatic stellate cells in pancreatic cancer. Pancreatology 2013; 13; 106-109.
9. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 2010; 11; 834-848.
10. Hasegawa Y, Yamamoto M, Maeda S, Saitoh Y. Hepatocyte growth-factor and its receptor C-met regulate both cell-growth and invasion of human pancreatic-cancer. Int. J. Oncol. 1995; 7; 877-881.
11. Di Renzo MF, Poulsom R, Olivero M et al. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res. 1995; 55; 1129-1138.
12. Kiehne K, Herzig KH, Folsch UR. c-met expression in pancreatic cancer and effects of hepatocyte growth factor on pancreatic cancer cell growth. Pancreas 1997; 15; 35-40.
13. Ohba N, Funatomi H, Seki T et al. Hepatocyte growth factor stimulates cell growth and enhances the expression of transforming growth factor alpha mRNA in AsPC-1 human pancreatic cancer cells. J. Gastroenterol. 1999; 34; 498-504.
14. Qian LW, Mizumoto K, Maehara N et al. Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production. Cancer Lett. 2003; 190; 105-112.
15. Avan A, Quint K, Nicolini F et al. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Curr. Pharm. Des. 2013; 19; 940-950.
16. Shah AN, Summy JM, Zhang J et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 2007; 14; 3629-3637.
17. Otte JM, Kiehne K, Schmitz F et al. C-met protooncogene expression and its regulation by cytokines in the regenerating pancreas and in pancreatic cancer cells. Scand. J. Gastroenterol. 2000; 35; 90-95.
18. Ebert M, Yokoyama M, Friess H et al. Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res. 1994; 54; 5775-5778.
19. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 2012; 12; 89-103.
20. Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat. Rev. Clin. Oncol. 2012; 9; 314-326.
21. Spigel DR, Ervin TJ, Ramlau RA et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2013; 31; 4105-4114.
22. Santoro A, Rimassa L, Borbath I et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013; 14; 55-63.
23. McShane LM, Altman DG, Sauerbrei W et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br. J. Cancer 2005; 93; 387-391.
24. Koeppen H, Yu W, Zha J et al. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib+/-onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin. Cancer Res. 2014; 20; 4488-4498.
25. Bachet JB, Marechal R, Demetter P et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann. Oncol. 2012; 23; 2327-2335.
26. Marechal R, Demetter P, Nagy N et al. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br. J. Cancer 2009; 100; 1444-1451.
27. Bonnetain F, Bonsing B, Conroy T et al. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). Eur. J. Cancer 2014; 50; 2983-2993.
28. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33; 159-174.
29. Furukawa T, Duguid WP, Kobari M et al. Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am. J. Pathol. 1995; 147; 889-895.
30. Ide T, Kitajima Y, Miyoshi A et al. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann. Surg. Oncol. 2007; 14; 2600-2607.
31. Zhu GH, Huang C, Qiu ZJ et al. Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma. Dig. Dis. Sci. 2011; 56; 1090-1098.
32. Gardian K, Janczewska S, Olszewski WL, Durlik M. Analysis of pancreatic cancer microenvironment: role of macrophage infiltrates and growth factors expression. J. Cancer 2012; 3; 285-291.
33. Gardian K, Janczewska S, Durlik M. Microenvironment elements involved in the development of pancreatic cancer tumor. Gastroenterol. Res. Pract. 2012; 2012; Article ID 585674 1-6.
34. Park JK, Kim MA, Ryu JK et al. Postoperative prognostic predictors of pancreatic ductal adenocarcinoma: clinical analysis and immunoprofile on tissue microarrays. Ann. Surg. Oncol. 2012; 19; 2664-2672.
35. Pennacchietti S, Michieli P, Galluzzo M et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3; 347-361.
36. Kitajima Y, Ide T, Ohtsuka T, Miyazaki K. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci. 2008; 99; 1341-1347.
37. Hill KS, Lorinczi M, Elferink LA. Altered down regulation of the receptor tyrosine kinase met in pancreatic adenocarcinoma cells. J. Exp. Ther. Oncol. 2010; 8; 297-312.
38. Hill KS, Gaziova I, Harrigal L et al. Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer. PLoS ONE 2012; 7; e40420.
39. Bauer TW, Somcio RJ, Fan F et al. Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol. Cancer Ther. 2006; 5; 1676-1682.
40. Hage C, Rausch V, Giese N et al. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis. 2013; 4; e627; 1-10.
41. Maehara N, Matsumoto K, Kuba K et al. NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. Br. J. Cancer 2001; 84; 864-873.
42. Avan A, Caretti V, Funel N et al. Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. Cancer Res. 2013; 73; 6745-6756.
43. Li C, Wu JJ, Hynes M et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011; 141; 2218-2227.
44. Zhang YW, Staal B, Essenburg C et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 2010; 70; 6880-6890.
45. Jin H, Yang R, Zheng Z et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 2008; 68; 4360-4368.
46. Tomioka D, Maehara N, Kuba K et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res. 2001; 61; 7518-7524.